Pharmaceutical

Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

Apr 30, 2025 - 06:00
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.
Read the original article

Tags:

Previous Article

US tariffs likely to disrupt drug development costs and prices, says GlobalData

Next Article

AstraZeneca CEO calls for increased European investment in pharma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Glenmark Pharma to divest 75% stake in life sciences un...

Sep 23, 2023

Opinion: Medicare has different standards than the FDA. That’s how it should be

Opinion: Medicare has different standards than the FDA....

Feb 3, 2024

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

STAT+: A Q&A with Vertex founder Joshua Boger on Casgev...

Dec 11, 2023